The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease

Affiliations

¹ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio.
² Department of Neurology, University of South Florida, Tampa.
³ Department of Neurology, University of Florida College of Medicine, Gainesville.

Editorial

Alberto J Espay et al. JAMA Neurol. 2020.

. 2020 Mar 1;77(3):295-297.

doi: 10.1001/jamaneurol.2019.3983.

¹ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio.
² Department of Neurology, University of South Florida, Tampa.
³ Department of Neurology, University of Florida College of Medicine, Gainesville.

No abstract available

Comment on

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.